Beam Therapeutics

Historical price data

Beam Therapeutics is a clinical-stage biotech leader in base editing, a next-generation gene editing technology designed for precise, single-base DNA corrections without double-strand breaks. The company's mission is to deliver durable, one-time cures for serious genetic diseases, with its lead program, BEAM-101 for sickle cell disease and beta-thalassemia, now in Phase 1/2 trials. Beam's strategy leverages a fully integrated platform spanning discovery, development, and in-house GMP manufacturing to build a broad pipeline and establish dominant intellectual property in the precision genetic medicine space.

Proprietary base editing platform enabling precise, single-letter DNA changes without creating double-strand breaks, utilizing cytosine and adenine base editors for correction, modulation, and multiplexed editing strategies.

Beam competes directly with CRISPR-Cas9 nuclease companies (e.g., CRISPR Therapeutics, Editas), other next-gen editing firms (e.g., Prime Medicine), and gene therapy/oligonucleotide developers. Its primary differentiation is the precision and safety profile of its non-cutting base editors, though it must continuously innovate to maintain its edge in a fast-moving field.